title: Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
abstract: BACKGROUND
  The aim of this study was to find out whether the beneficial effects of the renin-angiotensin-aldosterone system (RAS) blockage in chronic kidney disease (CKD) has any relation with the alteration of asymmetric dimethylarginine (ADMA) levels.
  
  
  METHODS
  Sixty-six nondiabetic patients with CKD and proteinuria and 36 healthy subjects were enrolled. Patients were treated with either ramipril 5 mg daily or valsartan 160 mg daily for 3 months. Proteinuria, ADMA, symmetric dimethyl arginine (SDMA), flow-mediated dilatation (FMD) and HOMA index measurements were performed both before and after the treatment.
  
  
  RESULTS
  ADMA, SDMA, hsCRP levels, HOMA index and proteinuria of patients were significantly higher (p < 0.001 for all) and FMD, L-arginine and L-arginine/ADMA ratio in CKD were significantly lower than controls. According to the multiple regression analysis, proteinuria levels were independently related to ADMA and SDMA levels.
  
  
  CONCLUSIONS
  Both drugs were equally effective in reducing elevated ADMA levels and improving endothelial dysfunction in CKD patients.
authors: Department of Nephrology, Gülhane School of Medicine, Etlik-Ankara, Turkey. mahmutiyilmaz@yahoo.com
authors: Mahmut Ilker
authors: MI
authors: Yilmaz
authors: Mutlu
authors: M
authors: Saglam
authors: Alper
authors: A
authors: Sonmez
authors: Kayser
authors: K
authors: Caglar
authors: Erdinc
authors: E
authors: Cakir
authors: Yasemin
authors: Y
authors: Kurt
authors: Tayfun
authors: T
authors: Eyileten
authors: Mustafa
authors: M
authors: Tasar
authors: Cengizhan
authors: C
authors: Acikel
authors: Yusuf
authors: Y
authors: Oguz
authors: Abdulgaffar
authors: A
authors: Vural
authors: Mujdat
authors: M
authors: Yenicesu
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D015415:Biomarkers; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D018056:Hemorheology; D006801:Humans; D007333:Insulin Resistance; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D017257:Ramipril / Q000494:pharmacology / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000068756:Valsartan; D014664:Vasodilation / Q000187:drug effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D001786:Blood Glucose; D008055:Lipids; D013777:Tetrazoles; C024917:symmetric dimethylarginine; C018524:N,N-dimethylarginine; D000068756:Valsartan; D002097:C-Reactive Protein; D001120:Arginine; D014633:Valine; D017257:Ramipril